Gunther Nussbaumer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gunther Nussbaumer has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Christof M. Kramm
Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
7 shared publications Martin Benesch
Division of Pediatric Hemato-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
7 shared publications- Thomas Perwein
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz , Graz
7 shared publications - Andre Oscar von Bueren
Department of Pediatrics, Gynecology and Obstetrics, Division of General Pediatrics, Pediatric Hematology and Oncology Unit, University Hospitals of Geneva, Geneva, Switzerland
5 shared publications - Michael Karremann
Department of Pediatric and Adolescent Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
5 shared publications - Angela Mastronuzzi
Area of Hematology-Oncology, Cell Therapy, Gene Therapies, and Hematopoietic Transplantation, Bambino Gesù Children’s Hospital, IRCCS
3 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Springer Nature in Journal of Neuro-Oncology Discovery
- Vol. 1 (1) , 9
Limited evidence for chemo- and radiosensitization by HDAC inhibitors in gliomasphere models of pediatric high-grade glioma
Purpose: Pediatric high-grade glioma (pedHGG), including diffuse intrinsic pontine glioma (DIPG) and non-pontine diffuse midline glioma, remains uniformly lethal despite radiotherapy and, in some protocols, temozolomide (TMZ). Recurrent histone H3 mutations reducing H3K27 trimethylation provide a rationale for histone deacetylase inhibitors (HDACi). We therefore asked whether HDAC inhibition can overcome intrinsic TMZ resistance. Methods: Six HDACi (vorinostat, panobinostat, valproic acid, domatinostat, mocetinostat, resminostat) were tested as single agents in three pedHGG models (HSJD-DIPG-007 [H3K27M], SF188 and HSJD-GBM-001 [H3 wildtype]) under gliomasphere and adherent conditions; TMZ and 8 Gy combinations were tested in gliomaspheres, valproic acid also in monolayer. Viability, morphology and histone acetylation were assessed; drug interactions were scored with HSA, ZIP, Loewe and Bliss, and radiation/TMZ response ratios. Results: All HDACi reduced viability concentration-dependently, panobinostat most and valproic acid least potently, and gliomaspheres were generally less sensitive than adherent cells. At concentrations referenced to reported plasma exposures, HDACi altered sphere morphology and showed a heterogeneous trend towards increased H3K27 acetylation, without statistically significant individual comparisons. Combination analyses revealed no reproducible synergy or radiosensitization in this screening-level assay; HSA scores above 10 were confined to SF188, and none exceeded this threshold across all four reference models. Only mocetinostat increased the TMZ-associated reduction in MTT signal in DIPG-007 at the supra-clinical TMZ concentration. Conclusions: Despite a trend consistent with target engagement, HDACi did not consistently enhance TMZ or irradiation efficacy in pedHGG and DIPG models under the conditions tested, underscoring the need for alternative, mechanism-informed combination strategies.
- 22 October 2026
- Published by Springer Nature in Journal of Neuro-Oncology Discovery
- Vol. 1 (1) , 9
Open AccessLimited evidence for chemo- and radiosensitization by HDAC inhibitors in gliomasphere models of pediatric high-grade glioma
Purpose: Pediatric high-grade glioma (pedHGG), including diffuse intrinsic pontine glioma (DIPG) and non-pontine diffuse midline glioma, remains uniformly lethal despite radiotherapy and, in some protocols, temozolomide (TMZ). Recurrent histone H3 mutations reducing H3K27 trimethylation provide a rationale for histone deacetylase inhibitors (HDACi). We therefore asked whether HDAC inhibition can overcome intrinsic TMZ resistance. Methods: Six HDACi (vorinostat, panobinostat, valproic acid, domatinostat, mocetinostat, resminostat) were tested as single agents in three pedHGG models (HSJD-DIPG-007 [H3K27M], SF188 and HSJD-GBM-001 [H3 wildtype]) under gliomasphere and adherent conditions; TMZ and 8 Gy combinations were tested in gliomaspheres, valproic acid also in monolayer. Viability, morphology and histone acetylation were assessed; drug interactions were scored with HSA, ZIP, Loewe and Bliss, and radiation/TMZ response ratios. Results: All HDACi reduced viability concentration-dependently, panobinostat most and valproic acid least potently, and gliomaspheres were generally less sensitive than adherent cells. At concentrations referenced to reported plasma exposures, HDACi altered sphere morphology and showed a heterogeneous trend towards increased H3K27 acetylation, without statistically significant individual comparisons. Combination analyses revealed no reproducible synergy or radiosensitization in this screening-level assay; HSA scores above 10 were confined to SF188, and none exceeded this threshold across all four reference models. Only mocetinostat increased the TMZ-associated reduction in MTT signal in DIPG-007 at the supra-clinical TMZ concentration. Conclusions: Despite a trend consistent with target engagement, HDACi did not consistently enhance TMZ or irradiation efficacy in pedHGG and DIPG models under the conditions tested, underscoring the need for alternative, mechanism-informed combination strategies.
- Open Access
- 17 June 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Bridging Borders in Pediatric Oncology: Cross-Regional Insights into Physical Exercise Program Perceptions in Europe, North Africa, and Arab Countries
Structured physical exercise programs (PEPs) in pediatric oncology have shown benefits for physical, psychosocial, and cognitive outcomes, yet their integration into routine care varies globally. This study explores health care professionals' perceptions of PEPs across European, North African, and Arab pediatric oncology centers, comparing attitudes between centers with and without established programs, based on findings from an international survey. A validated, 14-item, multilanguage questionnaire was distributed to health care professionals involved in pediatric oncology care, including physicians, nurses, physiotherapists, and sport therapists. Responses from 575 professionals (367 European; 208 North African/Arab) were analyzed, comparing perceptions according to region, profession, and PEPs availability at their centers. Overall, 97% of respondents with PEPs experience and 91% without considered PEPs beneficial. Perceived benefits extended beyond endurance and strength to mood, self-esteem, and quality of life, particularly among those with prior PEP exposure. European centers without PEP prioritized physical rehabilitation, whereas North African/Arab centers emphasized psychosocial benefits. Significant differences emerged regarding timing, setting, and relationship to physiotherapy. Most favored integrating PEP into standard care, with stronger support among experienced respondents. Across regions, health care professionals recognize PEP as a valuable adjunct in pediatric oncology. Cultural norms and resource availability shape program focus, with European centers leaning toward physical rehabilitation and North African/Arab centers prioritizing psychosocial support. Findings highlight the need for balanced, context-sensitive strategies that integrate both physical and psychosocial elements, ensuring equitable access and optimized patient outcomes in diverse health care settings.
- 17 June 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Open AccessBridging Borders in Pediatric Oncology: Cross-Regional Insights into Physical Exercise Program Perceptions in Europe, North Africa, and Arab Countries
Structured physical exercise programs (PEPs) in pediatric oncology have shown benefits for physical, psychosocial, and cognitive outcomes, yet their integration into routine care varies globally. This study explores health care professionals' perceptions of PEPs across European, North African, and Arab pediatric oncology centers, comparing attitudes between centers with and without established programs, based on findings from an international survey. A validated, 14-item, multilanguage questionnaire was distributed to health care professionals involved in pediatric oncology care, including physicians, nurses, physiotherapists, and sport therapists. Responses from 575 professionals (367 European; 208 North African/Arab) were analyzed, comparing perceptions according to region, profession, and PEPs availability at their centers. Overall, 97% of respondents with PEPs experience and 91% without considered PEPs beneficial. Perceived benefits extended beyond endurance and strength to mood, self-esteem, and quality of life, particularly among those with prior PEP exposure. European centers without PEP prioritized physical rehabilitation, whereas North African/Arab centers emphasized psychosocial benefits. Significant differences emerged regarding timing, setting, and relationship to physiotherapy. Most favored integrating PEP into standard care, with stronger support among experienced respondents. Across regions, health care professionals recognize PEP as a valuable adjunct in pediatric oncology. Cultural norms and resource availability shape program focus, with European centers leaning toward physical rehabilitation and North African/Arab centers prioritizing psychosocial support. Findings highlight the need for balanced, context-sensitive strategies that integrate both physical and psychosocial elements, ensuring equitable access and optimized patient outcomes in diverse health care settings.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag155
Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?
Background: Diffuse intrinsic pontine glioma (DIPG) remains uniformly lethal. Stereotactic biopsy confirms the diagnosis and enables molecular profiling. Metastasis along the biopsy track (BTM) has been reported only anecdotally; its prevalence, clinical relevance, and implications for treatment remain unclear. Methods: A multicenter retrospective study in patients with confirmed DIPG and BTM was conducted based on central neuroradiologic review. Radiotherapy schedules were re-assessed to evaluate the feasibility of upfront biopsy track irradiation. Results: Ten children met inclusion criteria (median age 6.8 years). Biopsy route was supratentorial in six and infratentorial in four children, and side-cutting needles were used predominantly. H3F3A mutations were most frequent (n = 8); TP53 alterations were common in tumors with extended molecular profiling available. Median PFS was 8.1 months. Five patients each developed BTM prior to (median 2.7 months) or concurrently with progression of primary tumor. There was no difference in overall survival (median OS 12.0 months) compared with the reference cohort. Estimated BTM prevalence among biopsied DIPG from additional registry data was between 6.9% and 13.0%. Primary biopsy track irradiation proved to be feasible, and comparing the surgical access routes, the infratentorial biopsy track hardly increased radiation exposure of the whole brain. Conclusions: Needle track metastasis is a rare progression pattern in stereotactic biopsied DIPG. Upfront irradiation of the biopsy track may represent a strategy to mitigate the potential risk of BTM. From a dosimetric perspective, an infratentorial approach may therefore be considered, as it was associated with only marginally increased radiation exposure.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag155
Open AccessNeedle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?
Background: Diffuse intrinsic pontine glioma (DIPG) remains uniformly lethal. Stereotactic biopsy confirms the diagnosis and enables molecular profiling. Metastasis along the biopsy track (BTM) has been reported only anecdotally; its prevalence, clinical relevance, and implications for treatment remain unclear. Methods: A multicenter retrospective study in patients with confirmed DIPG and BTM was conducted based on central neuroradiologic review. Radiotherapy schedules were re-assessed to evaluate the feasibility of upfront biopsy track irradiation. Results: Ten children met inclusion criteria (median age 6.8 years). Biopsy route was supratentorial in six and infratentorial in four children, and side-cutting needles were used predominantly. H3F3A mutations were most frequent (n = 8); TP53 alterations were common in tumors with extended molecular profiling available. Median PFS was 8.1 months. Five patients each developed BTM prior to (median 2.7 months) or concurrently with progression of primary tumor. There was no difference in overall survival (median OS 12.0 months) compared with the reference cohort. Estimated BTM prevalence among biopsied DIPG from additional registry data was between 6.9% and 13.0%. Primary biopsy track irradiation proved to be feasible, and comparing the surgical access routes, the infratentorial biopsy track hardly increased radiation exposure of the whole brain. Conclusions: Needle track metastasis is a rare progression pattern in stereotactic biopsied DIPG. Upfront irradiation of the biopsy track may represent a strategy to mitigate the potential risk of BTM. From a dosimetric perspective, an infratentorial approach may therefore be considered, as it was associated with only marginally increased radiation exposure.
- 11 October 2025
- Published by Elsevier in Clinical Oncology
- Vol. 48, 103956
Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma
- 11 October 2025
- Published by Elsevier in Clinical Oncology
- Vol. 48, 103956
Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma
- Open Access
- 6 July 2025
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 6
Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
- 6 July 2025
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 6
Open AccessTemozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
- Open Access
- 8 May 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (9) , 1723-1737
Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile
The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. Median overall survival (OS) was 15.5 months (interquartile range, 10.9–27.7) with a 2-years survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). By DNA methylation profiling (n=49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wildtype (n=31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n=19), pedHGG_A/B (n=6), and pedHGG_MYCN (n=5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wildtype subgroup, recurrent alterations in EGFR (n=10) and BCOR (n=9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wildtype subgroup TP53 alterations had a significant negative effect on OS. Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).
- 8 May 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (9) , 1723-1737
Open AccessGliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile
The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. Median overall survival (OS) was 15.5 months (interquartile range, 10.9–27.7) with a 2-years survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). By DNA methylation profiling (n=49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wildtype (n=31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n=19), pedHGG_A/B (n=6), and pedHGG_MYCN (n=5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wildtype subgroup, recurrent alterations in EGFR (n=10) and BCOR (n=9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wildtype subgroup TP53 alterations had a significant negative effect on OS. Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).
- Open Access
- 25 July 2023
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 14 (1) , 101-108
Boswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor promoting potential
- 25 July 2023
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 14 (1) , 101-108
Open AccessBoswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor promoting potential
- Open Access
- 1 June 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , i40-i41
HGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES
Gliomatosis cerebri (GC), a radiologically defined highly infiltrating supratentorial glioma, is no longer considered a distinct entity since the 2016 WHO classification for tumors of the central nervous system (CNS). So far, neither prognostic factors, nor molecular GC-associated features have been established. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive radiological, clinical and (epi-)genetic characterization. Within a median follow-up of 15.5 months (range, 2.3–138.8), 93 patients (89.4%) had died, four (3.8%) were lost to follow-up and seven (6.8%) were alive with stable/progressive disease. Median progression-free- (PFS) and overall survival (OS) were 8.6 months (interquartile range, 4.3–14.0) and 15.5 months (10.9–27.7), respectively. Available histopathological grading correlated significantly with median OS: CNS-WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). In GC with high-grade features, radiochemotherapy achieved longest PFS (median 9.6 months [5.7–14.0]). According to methylation profiling [n=49] and exome-sequencing [n=45], most cases were considered as IDH-/H3-wildtype gliomas (n=32/52, 61.5%) enriched with the subclasses pedHGG_RTK2A/B (n=19), pedHGG_A/B (n=6) and pedHGG_MYCN (n=5), but exhibited only one pedHGG_RTK1A/B/C case. Within the IDH-/H3-wildtype gliomas, EGFR-alterations were most common (n=10). Expected genetic alterations of unselected hemispheric pedHGG affecting CDKN2A/B, ATRX or PDGFRA were virtually absent. Additionally, we observed structural aberrations in chromosome 6 comprising complex genomic rearrangements, large areas of loss, or even gain/amplification at similar breakpoints in 16/49 cases (32.7%). We assembled the largest pediatric GC cohort providing evidence that GC may have a strong predilection to arise on the background of specific molecular features (pedHGG_RTK2A/B, pedHGG_A/B and pedHGG_MYCN; EGFR- and chromosome 6-alterations). Taken together, these findings expand on the current understanding of GC and provide insight into disease biology of extensively infiltrating gliomas in children.
- 1 June 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , i40-i41
Open AccessHGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES
Gliomatosis cerebri (GC), a radiologically defined highly infiltrating supratentorial glioma, is no longer considered a distinct entity since the 2016 WHO classification for tumors of the central nervous system (CNS). So far, neither prognostic factors, nor molecular GC-associated features have been established. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive radiological, clinical and (epi-)genetic characterization. Within a median follow-up of 15.5 months (range, 2.3–138.8), 93 patients (89.4%) had died, four (3.8%) were lost to follow-up and seven (6.8%) were alive with stable/progressive disease. Median progression-free- (PFS) and overall survival (OS) were 8.6 months (interquartile range, 4.3–14.0) and 15.5 months (10.9–27.7), respectively. Available histopathological grading correlated significantly with median OS: CNS-WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). In GC with high-grade features, radiochemotherapy achieved longest PFS (median 9.6 months [5.7–14.0]). According to methylation profiling [n=49] and exome-sequencing [n=45], most cases were considered as IDH-/H3-wildtype gliomas (n=32/52, 61.5%) enriched with the subclasses pedHGG_RTK2A/B (n=19), pedHGG_A/B (n=6) and pedHGG_MYCN (n=5), but exhibited only one pedHGG_RTK1A/B/C case. Within the IDH-/H3-wildtype gliomas, EGFR-alterations were most common (n=10). Expected genetic alterations of unselected hemispheric pedHGG affecting CDKN2A/B, ATRX or PDGFRA were virtually absent. Additionally, we observed structural aberrations in chromosome 6 comprising complex genomic rearrangements, large areas of loss, or even gain/amplification at similar breakpoints in 16/49 cases (32.7%). We assembled the largest pediatric GC cohort providing evidence that GC may have a strong predilection to arise on the background of specific molecular features (pedHGG_RTK2A/B, pedHGG_A/B and pedHGG_MYCN; EGFR- and chromosome 6-alterations). Taken together, these findings expand on the current understanding of GC and provide insight into disease biology of extensively infiltrating gliomas in children.
- 4 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (2) , e29895
Bilateral testicular juvenile granulosa cell tumor: Tumor control with conservative, antihormonal therapy
- 4 August 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (2) , e29895
Bilateral testicular juvenile granulosa cell tumor: Tumor control with conservative, antihormonal therapy